MedTrace Logo

A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

NCT03172494 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 720

Last updated 2022-12-14

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Asia. The aim of this trial is to confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus inadequately controlled on oral antidiabetic agents

Conditions

Interventions

DRUG

Insulin degludec/liraglutide

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

DRUG

Insulin degludec

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

DRUG

Liraglutide

Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. For 26 weeks.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR,1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-26
Primary Completion
2019-06-14
Completion
2019-07-13
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03172494 on ClinicalTrials.gov